首页> 外国专利> COMBINATION THERAPY FOR LOWER URINARY TRACT DISORDERS WITH A2O LEAGERS AND NSAIDS

COMBINATION THERAPY FOR LOWER URINARY TRACT DISORDERS WITH A2O LEAGERS AND NSAIDS

机译:降低尿道疾病与A2O引发剂和NSAIDS的联合治疗

摘要

α2α calcium channel subunit binder (α2d), non-steroidal antiinflammatory drug (α1α) and uses are the administration to a mammal of a combination of compounds, of which at least one is α2α channel subunit binder. Calcium (a2d) and at least one is a non-steroidal anti-inflammatory drug (aine), which provides a surprising and potent inhibition of the micturition reflex, superior to the inhibition obtained by treatment with an a2d or aine ligand alone. combinations of α2d and aines ligands are thus useful for the treatment of lower urinary tract disorders and symptoms thereof. Preferred α2d ligands are gabapentin and pregabalin. Preferred aines are celecoxib, diclofenac, diflunisal, flurbiprofen, naproxen, nimesulide or
机译:α2α钙通道亚基粘合剂(α2d),非甾体抗炎药(α1α)及其用途是向哺乳动物施用化合物的组合,其中至少一种是α2α通道亚基粘合剂。钙(a2d)和至少一种是非甾体类抗炎药(aine),它对排尿反射的抑制作用令人惊讶且有效,优于单独使用a2d或胺配体治疗获得的抑制作用。因此,α2d和胺的配体的组合可用于治疗下尿路疾病及其症状。优选的α2d配体是加巴喷丁和普瑞巴林。优选的胺类是塞来昔布,双氯芬酸,双氟尼,氟比洛芬,萘普生,尼美舒利或

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号